Search

Search Constraints

You searched for: Author/Creator Jo, Hitomi

Search Results

2. Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series. Issue 12 (21st October 2020)

3. Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients. (November 2022)